Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial - 05/08/19
, Emmy Okello, MD c, Daniel Engelman d, e, f, Anneke Grobler e, f, Amy Scheel g, Alyssa DeWyer h, Rachel Sarnacki h, Isaac Otim Omara c, Joselyn Rwebembera c, Craig Sable h, Andrew Steer d, e, fBackground |
Rheumatic heart disease (RHD) remains a high prevalence condition in low- and middle-income countries. Most individuals with RHD present late, missing the opportunity to benefit from secondary antibiotic prophylaxis. Echocardiographic screening can detect latent RHD, but the impact of secondary prophylaxis in screen-detected individuals is not known.
Methods/Design |
This trial aims to determine if secondary prophylaxis with every-4-week injectable Benzathine penicillin G (BPG) improves outcomes for children diagnosed with latent RHD. This is a randomized controlled trial in consenting children, aged 5 to 17 years in Northern Uganda, confirmed to have borderline RHD or mild definite RHD on echocardiography, according to the 2012 World Heart Federation criteria. Qualifying children will be randomized to every-4-week injectable intramuscular BPG or no medical intervention and followed for a period of 2 years. Ongoing intervention adherence and retention in the trial will be supported through the establishment of peer support groups for participants in the intervention and control arms. A blinded echocardiography adjudication panel consisting of four independent experts will determine the echocardiographic classification at enrollment and trajectory through consensus review.
The primary outcome is the proportion of children in the BPG-arm who demonstrate echocardiographic progression of latent RHD compared to those in the control arm. The secondary outcome is the proportion of children in the BPG-arm who demonstrate echocardiographic regression of latent RHD compared to those in the control arm. A sample size of 916 participants will provide 90% power to detect a 50% relative risk reduction assuming a 15% progression in the control group. The planned study duration is from 2018–2021.
Discussion |
Policy decisions on the role of echocardiographic screening for RHD have stalled because of the lack of evidence of the benefit of secondary prophylaxis. The results of our study will immediately inform the standard of care for children diagnosed with latent RHD and will shape, over 2–3 years, practical and scalable programs that could substantially decrease the burden of RHD in our lifetime.
Trial Registration |
ClinicalTrials.gov: NCT03346525. Date Registered: November 17, 2017.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| RCT# NCT03346525 |
Vol 215
P. 95-105 - Settembre 2019 Ritorno al numero
Articolo precedente
- Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design
- Miguel Valderrábano, Leif E. Peterson, Raquel Bunge, Michelle Prystash, Amish S. Dave, Sherif Nagueh, Neal S. Kleiman
- Danish study of Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): Study design for a controlled study of diagnostic accuracy
- Laust Dupont Rasmussen, Simon Winther, Jelmer Westra, Christin Isaksen, June Anita Ejlersen, Lau Brix, Jane Kirk, Grazina Urbonaviciene, Hanne Maare Søndergaard, Osama Hammid, Samuel Emil Schmidt, Lars Lyhne Knudsen, Lene Helleskov Madsen, Lars Frost, Steffen E. Petersen, Lars Christian Gormsen, Evald Høj Christiansen, Ashkan Eftekhari, Niels Ramsing Holm, Mette Nyegaard, Amedeo Chiribiri, Hans Erik Bøtker, Morten Böttcher
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?